Clinical comparative study of docetaxel or oxaliplatin combined with fluorouracil drugs in the treatment of advanced gastric cancer
10.7619/jcmp.201723015
- VernacularTitle:多西他赛与奥沙利铂联合氟尿嘧啶类药物治疗晚期胃癌的临床效果比较
- Author:
Yongqing WANG
1
;
Wen FAN
Author Information
1. 陕西省康复医院
- Keywords:
docetaxel;
oxaliplatin;
fluorouracil drugs;
advanced gastric cancer;
survival analysis
- From:
Journal of Clinical Medicine in Practice
2017;21(23):50-52
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe and compare the efficacy and safety of docetaxel or oxaliplatin combined with fluorouracil drugs in the treatment of advanced gastric cancer.Methods A total of 80 patients with advanced gastric cancer were randomly divided into observation group and control group,with 40 cases per group.The patients in the control group were treated with docetaxel combined with fluorouracil drugs for chemotherapy,while the patients in the observation group was treated with oxaliplatin combined with fluorouracil drugs for chemotherapy.The clinical outcomes,the overall survival (OS),the progression free survival (PFS) and the adverse advents during treatment in the two groups were observed and compared.Results There were no statistically significant differences in the distribution of the clinical outcomes and the clinical efficiency between the two groups (P ＞ 0.05).There were no statistically significant differences in the estimated median values of OS and PFS between the two groups (P ＞ 0.05).The incidence of white blood cell declining of the patients in the observation group was significantly lower,while the incidence of peripheral neurotoxicity was significantly higher than that in the control group,and there were statistically significant differences between the two groups (P ＜ 0.05).Conclusion In the treatment of advanced gastric cancer,the application of docetaxel combined with fluorouracil drugs for chemotherapy or oxaliplatin combined with fluorouracil drugs for chemotherapy can achieve basically equal therapeutic effects,but there are differences in the adverse advents.Both of them are the effective alternative in chemotherapy for advanced gastric cancer.
